Akın KAYA, Gökhan ÇELİK, İsmail SAVAŞ, Ural Özlem GÜRKAN, Hacer SAVAŞ, Eriş Banu GÜLBAY

Elevated levels of circulating matrix metalloproteinase-9 in non-small cell lung cancer patients

Bazı kanser tiplerinde artmış matriks metalloproteinaz (MMP) seviyelerinin tümör progresyonunda önemli rol oynadığı bildirilmiştir. Amacımız; akciğer kanserinde MMP-9'un tümör belirleyici olarak yararını ve serum MMP-9'un tümörün tipi, evresi, nodal yayılımı, metastazları ve prognozla ilişkilerini değerlendirmektir. Histolojik olarak tanı konulan 35 küçük hücreli dışı akciğer kanserli (KHDAK) ve sağlıklı 14 kontrolün kan örneklerinde MMP-9 seviyeleri ölçüldü. Kanserli grubun MMP-9 seviyeleri anlamlı yüksek bulundu (p< 0.001). Kanser tipi, evresi ve nodal yayüımı gibi klinik bulgular ile serumMMP-9 arasında anlamlı ilişki saptanamadı, istatistiksel anlamlılık bulunamamasına rağmen metastazlı hasta grubunun MMP-9 seviyeleri daha yüksek bulundu. Hastalardan 11 'i altıncı ayın sonunda takibimizden çıktı. Kalan hastalardan MMP-9 düzeyleri düşük olan sekizinden yedisi altı ayın sonuna kadar hayattaydı. MMP-9 düzeyi yüksek olan 16 hastadan yalnız 10'u. altı ayın sonuna kadar hayattaydı. Sonuç olarak; KHDAK'h hastaların takibinde metastaz belirleyicisi olarak MMP-9 kullanılabilir.

Küçük hücreli dışı akciğer kanserli hastalarda serum MMP-9 düzeyi

Elevated levels of matrix metalloproteinase have been implicated as playing important role in tumour progression in several types of cancers. Our aim was to determine whether these enzyme might be a useful tumour marker for lung cancer and also to evaluate the correlation of circulating levels of matrix metalloproteinase-9 (MMP-9) with tumour histology, staging, nodal status, metastasis and prognosis. Blood samples were collected from 35 nonsmall cell lung cancer patients who were diagnosed historically, and 14 healthy controls. The MMP-9 levels were significantly higher in the cancer group (p< 0.001). However no significant correlation between several clinical features (such as histology of the tumour, staging, tumour status, or nodal status) and plasma MMP-9 levels have been observed. Though it does not show statistical significance, more patients with metastasis seemed to have higher MMP-9 levels. At the end of six month 11 patients were out of fol-low-up. Among the remaining 24 patients eight patients had lower MMP-9 levels, seven were survivors at the end of six months. Sixteen patients had MMP-9 levels above the threshold. Only 10 haue survived! to six months. In conclusion MMP-9 can serve as a marker for metastasis and can be valuable in the follow-up of lung cancer patients.

PDF

___

1. Boyle P. Cancer, cigarette smoking and premature death in Europe: A review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Lung Cancer 1997; 17: 7-60.
2. Cox G, Jones JL, Andi A, et al. A biological staging model for operable non-small cell lung cancer. Thorax 2001; 55:561-6.
3. Hrabec E, Strek M,Nowak D,Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med 2001; 95: 1-4.
4. lizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999; 5:149-53.
5. Endo K, Maehara Y, Baba H, et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 1997; 17(3C): 2253-8.
6. Garzettl GG, Ciavettini A, Lucarini G, et al. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: Comparison with CA 125, Anticancer Res 1996; 16(4A): 2123-7.
7. Hayasaka A, Suzuki N, Fujimoto N, et al. Elevated plasma levels of matrix metalloprotelnase-9 (92-kd type IV collagenase/getatinase B) in hepatoceiluiar carcinoma. Hepatology 1996; 24: 1058-62,
8. Torii A, Kodera Y, Uesaka K, et al. Plasma concentration of matrix metalloproteinase-9 in gastric cancer. Br J Surg 1997; 84: 133-6.
9. Mountain CF. Revisions in the International System far Staging Lung Cancer. Chest 1997; 111: 1710-7.
10. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000; 18: 7135-49.
11. Zucker S, Lysik RM, Zarrabl MH, Moll U . M(r) 92.000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993; 53: 140-6.
12. Ylisirnio S, Hoyhtya M, Makitaro R, et al. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001; 7: 1633-7.
13. Arkona C, Wiederanders B. Expression, subcellular distribution and plasma membrane binding of cathepsln B and gelatinases in bone metastatic tissue. Biol Chem 1996; 377: 695-702.
14. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer-TlMP-1 as a prognostic marker. Anticancer Res 2000; 20:1311-6.
15. Kodate M, Kasai T, Hashimoto H, et al. Expression of matrix metalloproteinase (gelatinase) in Tl adenocarcinoma of the lung. Pathol Int 1997; 47: 461.